GlaxoSmithKline Seeks Swift Verdict in $400 Million Patent Dispute Amid Teva’s Opioid Settlements

A GlaxoSmithKline lawyer has urged a Delaware federal judge to expedite a decision in a substantial $400 million patent case against Teva Pharmaceuticals. This appeal is set against the backdrop of Teva’s recent significant settlements in various opioid-related cases, which collectively amount to billions of dollars. The ongoing litigation involves pivotal intellectual property rights and has far-reaching implications for both pharmaceutical companies. For more details, visit Law360.